Consensus Stryker Corporation London S.E.
Stocks
0R2S
US8636671013
Medical Equipment, Supplies & Distribution
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 333.58 USD | -0.56% |
|
-5.10% | -5.70% |
| 08-05 | Rothschild & Co Redburn Adjusts Stryker Price Target to $360 From $346 | MT |
| 08-03 | UBS Adjusts Stryker Price Target to $382 From $400, Maintains Buy Rating | MT |
Evolution of the Average Target: Stryker Corporation
Evolution of the Target Price: Stryker Corporation
Changes in Analyst Recommendations: Stryker Corporation
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +13.35% | |||||
| +19.66% | |||||
| +13.27% | |||||
| +40.04% | |||||
| - | - | +19.76% | |||
| +0.52% | |||||
| +37.78% | |||||
| - | - | - | |||
| Average | +20.63% | |||||
| Weighted average by Cap. | +14.83% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| UBS | |
| RBC Capital Markets | |
| Evercore ISI | |
| Truist Securities | |
| Raymond James | |
| Bernstein | |
| JPMorgan Chase | |
| Piper Sandler | |
| BTIG | |
| Jefferies & Co. | |
| Goldman Sachs | |
| Argus | |
| BMO Capital | |
| Leerink Partners | |
| Rothschild & Co Redburn | |
| Stifel Nicolaus | |
| TD Cowen | |
| Needham & Co. | |
| Canaccord Genuity | |
| Wells Fargo Securities | |
| Baird | |
| Citigroup | |
| Wolfe Research | |
| Barclays | |
| Oppenheimer | |
| Roth Capital Partners | |
| Nephron Research | |
| Deutsche Bank Securities | |
| Morgan Stanley | |
| Roth MKM | |
| DA Davidson | |
| BofA Securities | |
| Loop Capital | |
| KeyBanc Capital Markets | |
| Edward Jones | |
| Cowen | |
| SVB Leerink | |
| Credit Suisse | |
| Northland Securities |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SYK Stock
- 0R2S Stock
- Consensus Stryker Corporation
Select your edition
All financial news and data tailored to specific country editions
